Format

Send to

Choose Destination
Clin Genet. 2018 Oct;94(3-4):339-345. doi: 10.1111/cge.13405. Epub 2018 Jul 16.

The GBA p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies.

Author information

1
Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada.
2
Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada.
3
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Quebec, Canada.
4
Department of Hematology, Jewish General Hospital, McGill University, Montréal, Quebec, Canada.
5
Axe neurosciences du CHU de Québec, Université Laval, Québec, Canada.
6
Faculty of Medicine, Department of Medicine, Laval University, Québec, Canada.
7
Faculty of Medicine, McGill University, Montréal, Quebec, Canada.
8
McGill Parkinson Program and Neurodegenerative Diseases Group, Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada.
9
Department of Pharmacology & Therapeutics, McGill University, Montréal, Quebec, Canada.
10
Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
11
Department of Neurology, McGill University, Montreal General Hospital, Montreal, Québec, Canada.
12
Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada.
13
Hematology/Oncology, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Quebec, Canada.
14
Mark Freedman and Judy Jacobs Program for Gaucher Disease, Sinai Health System and University of Toronto, Toronto, Ontario, Canada.
15
Department of Human Genetics, McGill University, Montréal, Quebec, Canada.

Abstract

Biallelic GBA mutations cause Gaucher disease (GD), and heterozygous carriers are at risk for synucleinopathies. No founder GBA mutations in French-Canadians are known. GBA was fully sequenced using targeted next generation and Sanger sequencing in French-Canadian Parkinson disease (PD) patients (n = 436), rapid eye movement (REM)-sleep behavior disorder (RBD) patients (n = 189) and controls (n = 891). Haplotype, identity-by-descent (IBD) and principal component analyses (PCA) were performed using single nucleotide polymorphism-chip data. Data on GD patients from Toronto and Montreal were collected from patients' files. A GBA p.Trp378Gly mutation was identified in two RBD and four PD patients (1% of all patients combined), and not in controls. The two RBD patients had converted to DLB within 3 years of their diagnosis. Haplotype, IBD and PCA analysis demonstrated that this mutation is from a single founder. Out of 167 GD patients screened, 15 (9.0%) carried the p.Trp378Gly mutation, all in trans with p.Asn370Ser. Three (20%) of the GD patients with the p.Trp378Gly mutation had developed Parkinsonism, and 11 patients had family history of PD. The p.Trp378Gly mutation is the first French-Canadian founder GBA mutation to be described, which leads to synucleinopathies and to GD type 1 when in compound heterozygosity with p.Asn370Ser.

KEYWORDS:

GBA; Gaucher disease; Parkinson disease; REM sleep behavior disorder

PMID:
29920646
DOI:
10.1111/cge.13405

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center